TSI Investor Profile: Inmed
Featured Video
Company Brief
Proprietary Drug/Disease Targeting Tool
InMed’s proprietary bioinformatics algorithm assesses the different active sites on cannabinoids and screens them against approved drug structures, disease site receptors, genetic profiles of diseases, and the involvement of proteins and chemical metabolites in disease pathways. This program then selects specific cannabinoids (or combinations thereof) that might play a role in regulating diseases.
Summary
Fiscal Year-End: December
License Renewal Month: October 2017
Licenses: 1
Licensed Capacity: N/A
Number of Patients: N/A
Headquarters: Vancouver, BC
Financials (pro forma 09/30)
Cash on hand: $2.7mm
Fixed Investment: $5.72mm
Shareholders’ Equity: $17.8mm
Revenues – Last Quarter: N/A
Adj. Gross Margin: N/A
EPS: N/A
Capital Structure (07/31/17)
Last Financing: xx mm shares at $0.xx
Basic Shares: 97.20mm
Warrants: 14.1mm
Options: 14.7mm
Diluted Shares: 121.9mm
Highlights
- Broad portfolio of assets in dermatology, ocular diseases, additional indications and cannabinoid biosynthesis
- Positioning to achieve value-driving, near-term milestones with limited investment:
- Experienced team capable of building value in biopharmaceuticals
Growth Strategy
- Lead drug candidate in an orphan paediatric disease with high unmet medical need; final formulation development, toxicology and Ph1-2a clinical trials targeted for completion within 24 months from financing
- Biosynthesis of cannabinoids aimed to be commercial ready within 24 months from financing
- Active discussions to license production to U.S. operators
Differentiators
- Bioinformatics Database Proprietary computer-based drug/disease target screening tool
- Biosynthesis Proprietary cannabinoid manufacturing system
- Drug Development Pipeline Expedited drug development timelines, conservative clinical budget targeting high unmet medical conditions utilizing disease-specific formulations:
- INM-750 for Epidermolysis Bullosa – An orphan paediatric disease characterized by extremely fragile skin with no current approved therapies. Potential global market revenues of ~US$1B.
- INM-085 for Glaucoma – A serious eye disease with a global market of >US$5B
Drug Development
R&D Timelines
Strong Management Team
Eric A. Adams CEO + President - 25+ years’ experience in global biopharmaceutical business development, Sales, Marketing, M&A with enGene, QLT, Advanced Tissue Sciences, Abbott Laboratories, Fresenius AG
Dr. Sazzad Hossain Chief Scientific Officer, PhD, M.Sc. - 20+ years of academic/industry experience in drug discovery and product development at Xenon Pharmaceuticals, targeting pain, inflammation and cardiovascular diseases; and Canada’s National Research Council
Dr. Ado Muhammad Chief Medical Officer, MD, DPM, MFPM - Former Associate Medical Director at GW Pharmaceuticals specializing in the development of cannabinoid-based prescription medicines
Jeff Charpentier Chief Financial Officer + Corporate Secretary - 25+ years’ experience in biotech and technology companies including Lifebank Corp., Inex Pharmaceuticals, and Chromos Molecular Systems Inc.
Alexandra Mancini Sr. Vice President, Clinical and Regulatory Affairs, M.Sc. - 30 years’ global biopharmaceutical R&D experience with Sirius Genomics, Inex Pharmaceuticals, and QLT Inc.
Related Articles
InMed: A Text Book Lesson in how Biotechs Drive Share Value Through Innovation.
InMed announces results of a study co-sponsored with the University of British Columbia. The InMed-UBC study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye, resulting in enhanced drug uptake via the cornea and lens. This study further validates the Company’s capacity to conduct a wide spectrum of drug development activities
Why InMed's (CSE: IN; OTCQB: IMLFF) Ground Breaking Biosynthesis Program Adds Investor Value
We think that InMed’s proprietary technology could put $6.6 Billion in play and make it one of the strongest biotech stocks in the market. We also think InMed is in the right place at the right time to create real value for investors in the Industry. Here's a few reasons why.
New Cannabinoid Medicine Can Be Successfully Administered Via a Topical Gel Eye Lens
New cannabinoid medicine can be successfully administered via a topical gel lens into the eye, a new InMed-University of British Columbia study reports.
5 CANNABIS BIOTECH STOCKS TO WATCH
These 5 Biotechs including InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) have a combined market cap of over $4 Billion. What should investors know about future growth for these companies?
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) Biosynthesis Technology Demonstrates Robust Diversity
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) continues down the fast track with its proprietary technology for the microbial biosynthesis of cannabinoids
Taking Stock of InMed - InMed President and CEO Eric Adams Sits Down For Two In-Depth Interviews
InMed Pharmaceuticals Inc. (CNSX:IN) (OTCMKTS:IMLFF) CEO Eric Adams recently sat down for two separate interviews regarding InMed's proprietary biosynthesis process, their patent filings and their research on using cannabinoids to treat various diseases.
InMed Pharmaceuticals pursues medical qualities of cannabis — no smoke
People with such serious medical conditions as glaucoma and multiple sclerosis may smoke marijuana to deliver a range of chemicals that they believe helps improve their conditions. The problem is that a joint might just be one of the least effective methods to deliver some of the 90+ cannabinoids found in cannabis.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targets Specific Diseases with its Proprietary Biotechnologies
Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases.
How InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Breakthrough Biosynthesis Works - Video
There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
InMed Provides Updates On Cannabinoid-Based Drug Therapies For The Treatment Of Pain
InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), announced today additional pre-clinical results in the development of INM-405 for the treatment of pain.
InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board
InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), announces the addition of Dr. Mauro Maccarrone to its Scientific Advisory Board. Dr. Maccarrone has vast experience in the field of cannabinoid research.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Inclusion in CSE25 Index
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has been included in the CSE25 Index after qualifying as one of the 25 largest companies in the CSE Composite Index.